1. Home
  2. GLU vs ELTX Comparison

GLU vs ELTX Comparison

Compare GLU & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Global Utility of Beneficial Ownership

GLU

Gabelli Global Utility of Beneficial Ownership

N/A

Current Price

$19.09

Market Cap

114.7M

Sector

Finance

ML Signal

N/A

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$2.40

Market Cap

63.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLU
ELTX
Founded
2004
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.7M
63.3M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
GLU
ELTX
Price
$19.09
$2.40
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$18.00
AVG Volume (30 Days)
6.6K
261.7K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
8.60%
N/A
EPS Growth
N/A
39.29
EPS
0.62
N/A
Revenue
N/A
$2,301,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$31.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.68
$2.36
52 Week High
$21.69
$16.00

Technical Indicators

Market Signals
Indicator
GLU
ELTX
Relative Strength Index (RSI) 42.19 27.22
Support Level $18.90 N/A
Resistance Level $19.66 $3.32
Average True Range (ATR) 0.22 0.14
MACD -0.02 -0.01
Stochastic Oscillator 7.18 5.88

Price Performance

Historical Comparison
GLU
ELTX

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: